Can percent free prostate-specific antigen reduce the need for prostate biopsy?
In a recent multicenter study, percent free prostate-specific antigen (PSA) enhanced the specificity of PSA testing in prostate cancer screening. To determine whether the percent free PSA could be as effective in reducing the need for biopsy in a managed care setting as in an academic setting. Kaiser Permanente Northwest Region (Portland, Oregon) and Kaiser Permanente Oakland/Berkeley (California). Prospective blinded study conducted by using Hybritech Tandem PSA and Hybritech Tandem free PSA assays (Beckman Coulter, Inc., Fullerton, California). 250 men (63 with prostate cancer and 187 with benign prostate conditions) who were older than 40 years of age, had a PSA level of 4.0 to 10.0 ng/mL, and had a histologically confirmed diagnosis. Sensitivity and specificity of percent free PSA. The median percent free PSA values for patients with cancer (free PSA, 13%) significantly differed from that for patients without cancer (free PSA, 17%) (P = 0.001). When a free PSA cutoff of 25% was used, the sensitivity was 97% (95% CI, 92% to 100%) and the specificity was 13% (CI, 8% to 18%). These results were not significantly different from those obtained in the multicenter study (95% sensitivity, 20% specificity for a free PSA cutoff of 25%). The results obtained in a managed care organization were similar to those obtained at large university medical centers and show that the percent free PSA can be used to enhance the specificity of PSA testing for prostate cancer.